Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Vinge top ranked within intellectual property law

Vinge’s IP practice group is once again top ranked in IAM’s annual ranking Patent 1000. Håkan Borgenhäll, Malin Malm Waerme and Stojan Arnerstål also receive individual recommendations.
July 06, 2022

New Regulation on foreign subsidies – the Council and the EP has reached an agreement

On 30 June, the Council and the European Parliament reached a provisional political agreement on a new Foreign Subsidies Regulation, based on a proposal by the Commission of 5 May 2021.
July 05, 2022

New partners and counsel appointed at Vinge’s Malmö and Stockholm offices

Advokat Daniel Daun and advokat Victor Ericsson at Vinge’s Malmö and Stockholm offices respectively have been appointed as new partners as of 1 January 2023. Jacob Jeanrond, Caroline Krassén, Henrik Schön, Maria Dahlin Kolvik, Sara Strandberg and Linn Adelwald have been elected as counsel at Vinge’s Stockholm office.
June 30, 2022